--- title: "Jupiter Neurosciences (JUNS) news: going concern and IPO" url: "https://aibio.space/companies/jupiter-neurosciences/" publisher: "aibio.space (Biotech Investor Relations News)" summary: "JUNS going concern, IPO and Nasdaq notice news: Jupiter Neurosciences gets two Nasdaq notices on minimum bid price and market value." --- JUNS Jupiter Neurosciences, Inc. NASDAQ · United States # Jupiter Neurosciences (JUNS) news JUNS going concern, IPO and Nasdaq notice news Listings · 2026-02-27 ## [Jupiter Neurosciences gets two Nasdaq notices on minimum bid price and market value](https://aibio.space/news/jupiter-neurosciences-gets-two-nasdaq-notices-minimum-bid-price-market/) Nasdaq says the stock closed below $1.00 for 30 consecutive business days and that its market value of listed securities stayed below $35 million. The company has until August 25, 2026 on both, and its auditor has raised going-concern doubt. ## Latest Jupiter Neurosciences news 1. 2025-08-14 Distress [Jupiter Neurosciences delays quarterly report for period ended June 30, 2025](https://aibio.space/news/jupiter-neurosciences-delays-quarterly-report-period-ended-june-30/) Jupiter said it needs more time to complete the presentation and review of its financial statements. It expects to file within five calendar days of the deadline and says it anticipates no significant change in results. 2. 2025-07-10 Listings [Jupiter Neurosciences regains compliance with Nasdaq $1.00 minimum bid price rule](https://aibio.space/news/jupiter-neurosciences-regains-compliance-nasdaq-1-00-minimum-bid-price/) Nasdaq confirmed on July 9, 2025 that Jupiter's stock held an average closing price of at least $1.00 over 13 days. The company's last annual report still carries a going concern warning. 3. 2025-03-25 Listings [Jupiter Neurosciences gets Nasdaq minimum bid price deficiency notice](https://aibio.space/news/jupiter-neurosciences-gets-nasdaq-minimum-bid-price-deficiency-notice/) Jupiter Neurosciences received a Nasdaq letter on March 21, 2025 saying its stock fails the $1.00 minimum bid price rule. The company has until September 17, 2025 to regain compliance. 4. 2024-12-02 Financings [Jupiter Neurosciences prices $11 million IPO of 2,750,000 shares at $4.00](https://aibio.space/news/jupiter-neurosciences-prices-11-million-ipo-2-750-000-shares-4-00/) Jupiter Neurosciences priced a firm commitment IPO of 2,750,000 shares at $4.00, or $11,000,000 gross. Its prospectus carries a going concern warning and an accumulated deficit of $23,903,481 at June 30, 2024. ## Jupiter Neurosciences at a glance - **Ticker**: JUNS - **Listing**: NASDAQ - **Country**: United States ### Related companies - [Obsidian Therapeutics](https://aibio.space/companies/obsidian-therapeutics/) NASDAQ: OBX - [Pulmatrix](https://aibio.space/companies/pulmatrix/) NASDAQ: PULM - [Lisata Therapeutics](https://aibio.space/companies/lisata-therapeutics/) NASDAQ: LSTA - [SELLAS Life Sciences Group](https://aibio.space/companies/sellas-life-sciences/) NASDAQ: SLS - [Fulcrum Therapeutics](https://aibio.space/companies/fulcrum-therapeutics/) NASDAQ: FULC - [Erasca](https://aibio.space/companies/erasca/) NASDAQ: ERAS - [Biomea Fusion](https://aibio.space/companies/biomea-fusion/) NASDAQ: BMEA - [Corvus Pharmaceuticals](https://aibio.space/companies/corvus-pharmaceuticals/) NASDAQ: CRVS ### Also on NASDAQ - [ADARx Pharmaceuticals](https://aibio.space/companies/adarx-pharmaceuticals/) ADRX - [Denali Therapeutics](https://aibio.space/companies/denali-therapeutics/) DNLI - [Arbutus Biopharma](https://aibio.space/companies/arbutus-biopharma/) ABUS - [Syndax Pharmaceuticals](https://aibio.space/companies/syndax-pharmaceuticals/) SNDX - [electroCore](https://aibio.space/companies/electrocore/) ECOR - [Ceribell](https://aibio.space/companies/ceribell/) CBLL ## What Jupiter Neurosciences does Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company in Jupiter, Florida. It is developing treatments for neuroinflammation and central nervous system (CNS) disorders and rare diseases using its JOTROL resveratrol platform, an enhanced oral formulation of resveratrol. Its primary target is Parkinson's disease, where it is conducting a Phase IIa clinical trial. The company says the IND for that trial received final FDA approval in November of 2025, and the trial is expected to start in the second quarter of 2026, with results anticipated 12 months later. It also aims to investigate Mild Cognitive Impairment and Alzheimer's disease after the Parkinson's study. The company has service agreements with firms in Hong Kong to accelerate product development in Southeast Asia, and an agreement with Dominant Treasure Health to expand business development in China, Malaysia and Singapore. It also sells Nugevia, a consumer line of nutritional products for longevity and wellness, sold direct-to-consumer through social media. Shipments began in the fourth quarter of 2025. The company reports two segments: premium nutritional supplements under the Nugevia brand, and pharmaceutical operations centered on drug candidates. | Product or program | What it is | Stage | |---|---|---| | JOTROL | Enhanced oral formulation of resveratrol, the company's platform product | Phase IIa in Parkinson's disease, expected to start second quarter 2026 | | Nugevia GLO | Consumer supplement supporting cellular function and skin vitality | available for sale | | Nugevia MND | Consumer supplement supporting cognitive resilience | available for sale | | Nugevia PWR | Consumer supplement supporting mitochondrial function | available for sale | Summarised from the company's [10-K filed Apr 1, 2026](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/form10-k.htm). ## Jupiter Neurosciences annual financials | Line | FY2025 | FY2024 | |---|---|---| | Revenue | [$21,796](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/) | | | Research and development | [$2.1 million](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/) | [$492,660](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/) | | Net income (loss) | [-$8.6 million](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/) | [-$2.4 million](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/) | | Cash from operations | [-$5.4 million](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/) | [-$3.9 million](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014687/) | Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice. ## Questions about Jupiter Neurosciences Has Jupiter Neurosciences issued a going-concern warning? Our latest story on this, dated Feb 27, 2026: "Jupiter Neurosciences gets two Nasdaq notices on minimum bid price and market value". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jupiter-neurosciences-gets-two-nasdaq-notices-minimum-bid-price-market/). When did Jupiter Neurosciences go public? Our latest story on this, dated Dec 2, 2024: "Jupiter Neurosciences prices $11 million IPO of 2,750,000 shares at $4.00". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jupiter-neurosciences-prices-11-million-ipo-2-750-000-shares-4-00/). Has Jupiter Neurosciences received a Nasdaq deficiency notice? Our latest story on this, dated Feb 27, 2026: "Jupiter Neurosciences gets two Nasdaq notices on minimum bid price and market value". The story links the filing or release it is based on. [Read the story](https://aibio.space/news/jupiter-neurosciences-gets-two-nasdaq-notices-minimum-bid-price-market/). What is the ticker symbol of Jupiter Neurosciences? Jupiter Neurosciences, Inc. trades under the ticker JUNS on NASDAQ. Where is Jupiter Neurosciences listed? Jupiter Neurosciences, Inc. is listed on NASDAQ. What is the SEC CIK of Jupiter Neurosciences? The SEC Central Index Key (CIK) for Jupiter Neurosciences, Inc. is 1679628. Its filings are on SEC EDGAR. How many shares does Jupiter Neurosciences have outstanding? 770,081 shares as of 2026-08-14, per the cover page of its 10-Q filed 2026-08-14. Which country or territory is Jupiter Neurosciences listed under? Our directory records Jupiter Neurosciences, Inc. under United States. What does Jupiter Neurosciences do? Our directory classifies Jupiter Neurosciences, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline. What is the ISIN of Jupiter Neurosciences? The ISIN recorded for Jupiter Neurosciences, Inc. is US48208B3024. Does aibio.space cover Jupiter Neurosciences? aibio.space lists Jupiter Neurosciences, Inc. among 2,820 public biotech companies and publishes its news here as stories appear. Where is Jupiter Neurosciences incorporated? SEC records list its state or country of incorporation as DE. What does Jupiter Neurosciences develop? Jupiter Neurosciences, Inc. is a clinical stage research and development pharmaceutical company in Jupiter, Florida. It is developing treatments for neuroinflammation and central nervous system (CNS) disorders and rare diseases using its JOTROL resveratrol platform, an enhanced oral formulation of resveratrol. What is JOTROL from Jupiter Neurosciences? JOTROL: Enhanced oral formulation of resveratrol, the company's platform product Stage: Phase IIa in Parkinson's disease, expected to start second quarter 2026. What is Nugevia GLO from Jupiter Neurosciences? Nugevia GLO: Consumer supplement supporting cellular function and skin vitality Stage: available for sale. ## Investor discussion: Jupiter Neurosciences Members talk about Jupiter Neurosciences (JUNS). Reader posts, not aibio.space reporting, and not investment advice. Rules 1. **Securities violations are strictly forbidden.** No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information. 2. **Say whether you hold the stock.** Every post states long, short or no position. 3. **No paid or sponsored posts.** Do not post for anyone who pays or rewards you. 4. **No buy or sell calls and no price targets.** 5. **No accusations of crime or fraud against named people** unless you link a court filing or a regulator's release that makes them. 6. **No personal details and no spam.** No links at all for your first 7 days as a member. Posts that break the rules may be deleted without notice, and the account restricted or closed. See the [terms](https://aibio.space/terms/#discussion) and the [privacy policy](https://aibio.space/privacy/#discussion). ## Capital-markets timeline Financings, listing notices, splits, legal actions and other investor events at Jupiter Neurosciences, newest first. Each line links the filing it comes from. 1. 2026-08-28 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226040577/form8-k.htm) 2. 2026-08-24 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226039784/form424b5.htm) 3. 2026-08-24 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226039886/form8-k.htm) 4. 2026-08-06 Listings Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226036279/ex99-1.htm) 5. 2026-07-27 Listings Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 5.07,8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226034724/form8-k.htm) 6. 2026-07-21 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226034077/form8-k.htm) 7. 2026-06-22 Listings Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226029491/formdef14a.htm) 8. 2026-06-09 Listings Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226027920/formpre14a.htm) 9. 2026-05-21 Financings Reported a financing. SEC Form 424B5. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226024740/form424b5.htm) 10. 2026-04-01 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226014681/formnt-10k.htm) 11. 2026-02-27 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,7.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226008344/form8-k.htm) 12. 2026-02-20 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315226007624/form8-k.htm) 13. 2025-12-23 Financings Reported an unregistered sale of its securities. SEC Form 8-K (Items 1.01,2.03,3.02,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315225029124/form8-k.htm) 14. 2025-11-26 Financings Filed a registration statement for a share offering. SEC Form S-1. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315225025204/forms-1.htm) 15. 2025-10-27 Financings Reported a financing. SEC Form 8-K (Items 1.01,2.03,3.02,7.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315225019783/ex99-1.htm) 16. 2025-08-14 Distress Told the SEC a periodic report would be filed late. SEC Form NT 10-Q. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000164117225024108/formnt10-q.htm) 17. 2025-07-10 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 8.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000164117225018619/ex99-1.htm) 18. 2025-04-21 Legal Reported a change of independent auditor. SEC Form 8-K (Items 4.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000164117225005506/form8-k.htm) 19. 2025-03-28 Distress Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-K. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000164117225001261/form10-k.htm) 20. 2025-03-25 Listings Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01,9.01). [Source](https://www.sec.gov/Archives/edgar/data/1679628/000164117225000627/form8-k.htm) 21. 2024-12-02 Financings Reported a financing. SEC Form 424B4. [Source](https://www.sec.gov/Archives/edgar/data/1679628/000149315224048318/form424b4.htm) ## Stock chart Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. [Open NASDAQ:JUNS on TradingView](https://www.tradingview.com/symbols/NASDAQ-JUNS/). ## SEC filings and registration - **SEC name**: Jupiter Neurosciences, Inc. - **CIK**: 1679628 - **Industry (SIC)**: Pharmaceutical Preparations (2834) - **US tickers**: JUNS (Nasdaq) - **State or country of incorporation**: DE - **Fiscal year ends**: December 31 - **Filer category**:
Emerging growth company - **Business address**: 1001 NORTH US HWY 1, JUPITER, FL, 33477 - **Phone**: (561) 406-6154 - **Shares outstanding**: 770,081 as of 2026-08-14 (10-Q filed 2026-08-14) - **Former names**: Jupiter Orphan Therapeutics, Inc. ### Recent filings (8-K and 6-K are the company's own announcements) - [S-3](https://www.sec.gov/Archives/edgar/data/1679628/000149315226044210/forms-3.htm) filed 2026-09-25 - [8-K](https://www.sec.gov/Archives/edgar/data/1679628/000149315226041315/form8-k.htm) filed 2026-09-03 - [8-K](https://www.sec.gov/Archives/edgar/data/1679628/000149315226040577/form8-k.htm) filed 2026-08-28 - [8-K](https://www.sec.gov/Archives/edgar/data/1679628/000149315226040308/form8-k.htm) filed 2026-08-27 - [8-K](https://www.sec.gov/Archives/edgar/data/1679628/000149315226039886/form8-k.htm) filed 2026-08-24 - [8-K](https://www.sec.gov/Archives/edgar/data/1679628/000149315226039785/form8-k.htm) filed 2026-08-24 - [424B5](https://www.sec.gov/Archives/edgar/data/1679628/000149315226039784/form424b5.htm) filed 2026-08-24 - [10-Q](https://www.sec.gov/Archives/edgar/data/1679628/000149315226038463/form10-q.htm) filed 2026-08-14 Source: [SEC EDGAR](https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001679628), retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices. ## Listing details Jupiter Neurosciences, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker JUNS, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them. - **Company**: Jupiter Neurosciences, Inc. - **Ticker**: JUNS - **Listing**: NASDAQ - **Country or territory**: United States - **Business scope**: Pharmaceuticals: Major - **ISIN**: US48208B3024 - **Last quote in directory**: 2026-10-21 - **Directory source**: [Listing page](https://www.tradingview.com/symbols/NASDAQ-JUNS/) Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. [Tell us about a change](https://aibio.space/reputation/#update). Work at this company? [Claim this page](https://aibio.space/claim/). Published and maintained by aibio.space. Not investment advice. [How we work](https://aibio.space/disclosures/). Who manages this page **This page is managed by aibio.space.** The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. [How we work](https://aibio.space/disclosures/#paid) · [Terms](https://aibio.space/terms/#news) · [Request a correction](https://aibio.space/reputation/#update) --- Source page: https://aibio.space/companies/jupiter-neurosciences/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Jupiter Neurosciences (JUNS) news: going concern and IPO", 2026-10-31, https://aibio.space/companies/jupiter-neurosciences/